CUE insider trading — Cue Biopharma, Inc.
Over the last 90 days, insiders at Cue Biopharma, Inc. (CUE) made 0 open-market purchases worth $0 and 7 open-market sales worth $2.43M, making them net sellers by $2.43M. The largest sale was by Lin Shao-Lee (Chief Executive Officer), who sold 40,000 shares for $1.08M on Aug 12, 2026.
Updated Oct 16, 2026.
Recent CUE insider transactions
Every Form 4 filed by Cue Biopharma, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | Ray Sumita | Chief Legal Compliance Officer | S · Sale | Direct | 1,844 | $28.05 | $52K | Form 4 |
| Oct 12, 2026 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | S · Sale | Direct | 1,144 | $28.05 | $32K | Form 4 |
| Oct 12, 2026 | Lin Shao-Lee | Chief Executive Officer | S · Sale | Direct | 11,087 | $27.55 | $305K | Form 4 |
| Aug 13, 2026 | Ray Sumita | Chief Legal Compliance Officer | M · Option exercise | Direct | 18,196 | — | — | Form 4 |
| Aug 13, 2026 | Ray Sumita | Chief Legal Compliance Officer | S · Sale | Direct | 8,829 | $30.09 | $266K | Form 4 |
| Aug 13, 2026 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | M · Option exercise | Direct | 13,647 | — | — | Form 4 |
| Aug 13, 2026 | Meluzio Michael Vincent | VP, Prin. Accounting Officer | S · Sale | Direct | 5,628 | $30.09 | $169K | Form 4 |
| Aug 13, 2026 | Lin Shao-Lee | Chief Executive Officer | S · Sale | Direct | 18,258 | $28.62 | $523K | Form 4 |
| Aug 12, 2026 | Lin Shao-Lee | Chief Executive Officer | M · Option exercise | Direct | 109,179 | — | — | Form 4 |
| Aug 12, 2026 | Lin Shao-Lee | Chief Executive Officer | S · Sale | Direct | 40,000 | $27.10 | $1.08M | Form 4 |
| Jul 30, 2026 | Ahlers James M | Chief Financial Officer | A · Grant/award | Direct | 25,500 | — | — | Form 4 |
CUE insider trading FAQ
Are insiders buying CUE stock?
Not on the open market. In the last 90 days, Cue Biopharma, Inc. insiders made no open-market purchases, and 7 open-market sales totaling $2.43M. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading CUE?
Recent sellers: Lin Shao-Lee, Meluzio Michael Vincent, Ray Sumita.
Where does CUE insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.